Neurologic toxicity, including ICANS, and serious or fatal reactions can occur with TALVEY^®1

Neurologic toxicity, including ICANS, occurred in 55% of patients who received TALVEY^® at the recommended dosages; Grade 3 or 4 events occurred in 6% of patients

• Most frequent neurologic toxicities were headache (20%), encephalopathy (15%), sensory neuropathy (14%), and motor dysfunction, including ataxia/cerebellar ataxia (10%)

ICANS was reported in 9% of 265 patients where ICANS data were collected and who received TALVEY^® at the recommended dosages

• Recurrent ICANS occurred in 3% of patients
• ICANS can occur concurrently with CRS, following resolution of CRS, or in the absence of CRS
• Clinical signs and symptoms of ICANS may include but are not limited to confusional state, depressed level of consciousness, disorientation, somnolence, lethargy, and bradyphrenia
• Advise patients to refrain from driving or operating heavy or potentially dangerous machinery during the step-up dosing schedule and for 48 hours after completion of the step-up dosing schedule, and in the event of new onset of any neurological symptoms, until symptoms resolve